Recombinant Human VEGF-C (Cys156Ser) Protein Summary
Details of Functionality |
Measured in a cell proliferation assay using HMVEC human microvascular endothelial cells. Marconcini, L. et al. (1999) Proc. Natl. Acad. Sci. USA 96:9671. The ED 50 for this effect is 1-5 µg/mL. Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGF R3/Flt‑4 Fc Chimera (Catalog # 349-F4) at 5 µg/mL (100 µL/well) can bind Recombinant Human VEGF‑C (Cys156Ser) with an apparent K d <40 nM. |
Source |
Mouse myeloma cell line, NS0-derived human VEGF-C protein Thr103-Arg227 (Cys156Ser), with a C-terminal 10-His tag |
Accession # |
|
N-terminal Sequence |
Thr103 |
Protein/Peptide Type |
Recombinant Proteins |
Gene |
VEGFC |
Purity |
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. |
Endotoxin Note |
<0.10 EU per 1 μg of the protein by the LAL method. |
Applications/Dilutions
Dilutions |
- Binding Activity
- Bioactivity
|
Theoretical MW |
15.4 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
SDS-PAGE |
22-24 kDa, reducing conditions |
Publications |
Read Publications using 752-VC in the following applications:
|
|
Packaging, Storage & Formulations
Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
|
Buffer |
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein. |
Purity |
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. |
Reconstitution Instructions |
Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin |
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Recombinant Human VEGF-C (Cys156Ser) Protein
Background
Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a subfamily of the angiogenic VEGF angiogenic factors (1). VEGF-C is synthesized as a 58 kDa molecule that consists of a VEGF homolgy domain (VHD) flanked by N- and C-terminal propeptides. The proprotein undergoes covalent homodimerization and stepwise proteolytic processing to generate ligands with increasing affinity for VEGF R3/Flt-4 (2-4). Fully processed VEGF-C containing just the 21 kDa VHD can additionally bind and activate VEGF R2/KDR/Flk-1 (2, 4). Fully processed human VEGF-C shares 98% amino acid sequence identity with mouse and rat VEGF-C. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis (5-8). VEGF-C and VEGF R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, resulting in enhanced lymph flow and metastasis to regional lymph nodes (9-12). It also induces physiological and intratumoral neoangiogenesis and vessel sprouting through interactions with VEGF R2 (8, 13, 14).
- Chen, J.-C. et al. (2013) Int. J. Mol. Sci. 14:88.
- Joukov, V. et al. (1996) EMBO J. 15:290.
- Kukk, E. et al. (1996) Development 122:3829.
- Joukov, V. et al. (1997) EMBO J. 16:3898.
- Karkkainen, M. et al. (2004) Nat. Immunol. 5:74.
- Jeltsch, M. et al. (1997) Science 276:1423.
- Makinen, T. et al. (2001) Nat. Med. 7:199.
- Laakkonen, P. et al. (2007) Cancer Res. 67:593.
- Hoshida, T. et al. (2006) Cancer Res. 66:8065.
- Mandriota, S.J. et al. (2001) EMBO J. 20:672.
- Skobe, M. et al. (2001) Nat. Med. 7:192.
- Padera, T.P. et al. (2002) Science 296:1883.
- Tammela, T. et al. (2008) Nature 454:656.
- Cao, Y. et al. (1998) Proc. Natl. Acad. Sci. 95:14389.
Customers Who Viewed This Item Also Viewed...
Species: Hu
Applications: ELISA
Species: Hu
Applications: ELISA
Species: Mu
Applications: CyTOF-ready, Flow, WB
Species: Mu
Applications: Dual ISH-IHC, IHC, WB
Species: Mu
Applications: CyTOF-ready, Dual ISH-IHC, Flow, IHC, Neut, WB
Species: Hu
Applications: Block, CyTOF-ready, Flow, IHC, WB
Species: Mu
Applications: IHC, Simple Western, WB
Species: Hu, Rt
Applications: IHC, IHC-Fr, IHC-P, Simple Western, WB
Species: Hu
Applications: ELISA
Species: Hu
Applications: BA
Species: Hu
Applications: WB
Species: Hu
Applications: WB
Species: Hu, Mu, Rt
Applications: CyTOF-ready, Flow, ICC, IHC, Simple Western, WB
Species: Hu
Applications: ChIP, ELISA, ICC/IF, WB
Species: Rt
Applications: IHC, WB
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-P, WB
Additional VEGF-C Products
Blogs on VEGF-C